"Swallow my Urine Back" : Inhibition of Detrusor Overactivity by Swallowing Maneuver

NCT ID: NCT01408771

Last Updated: 2011-08-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-04-30

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to find out whether swallowing has an effect on the degree of urinary urgency and on the amplitude of detrusor contraction during filling cystometry in patients with detrusor overactivity (DO).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Consecutive patients with DO will be included in this study. During urodynamics, the amplitude of the waves of DO will be documented and compared. At the beginning of the 2nd wave, patients will be asked to perform 5 repetitive swallows. Following each wave, patients will be asked to grade the severity of the urgency by a visual analogue scale (VAS).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Detrusor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

patients with DO in filling cystometry

* antimuscarinic medications were requested to stop for 7 days before the cystometry
Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assaf-Harofeh Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Assaf-Harofeh Medical Center

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kobi Stav, MD

Role: PRINCIPAL_INVESTIGATOR

Assaf Harofeh Medical Center, Zeriffin, Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

35/11

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.